No Data
No Data
Zhejiang Huahai Pharmaceutical Co., Ltd. Pre-performance announcement for the first three quarters of 2024
Huahai Pharma Gets US FDA's Provisional Approval for Diabetes Drug
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) Screens Well But There Might Be A Catch
China Approves Zhejiang Huahai Pharmaceutical's Hypertension, Schizophrenia Drugs
Zhejiang Huahai Pharmaceutical (600521.SH): Enalapril Maleate Tablets Obtained Pharmaceutical Registration Certificate.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company and its subsidiary, Changxing Pharmaceutical Co., Ltd. (abbreviated as Changxing Pharmaceutical, securities code: 835269), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The name of the pharmaceutical is "Perindopril Maleate Tablet". Perindopril Maleate Tablet is mainly used to treat primary hypertension at all stages, renal vascular hypertension, various stages of heart failure, prevent symptomatic heart failure, and prevent coronary artery ischemic events in patients with left ventricular dysfunction.
Zhejiang Huahai Pharmaceutical Gets US FDA Approval for Chemotherapy Injection
No Data
No Data